Physicians were asked to report how frequently (1 = always, 2 = frequently, 3 = not so often, 4 = rarely, 5 = never) they used trastuzumab in HER2+ breast cancer patients in different clinical settings. Here, ERBB2 is linked to breast carcinoma.